As of April 3, 2006, Abgenix, Inc. was acquired by Amgen, Inc. Abgenix, Inc., a biopharmaceutical company, engages in the discovery, development, and manufacture of human therapeutic antibodies for the treatment of various disease conditions, including cancer, inflammation, and metabolic disease. Its antibody therapeutic product candidates, which are in clinical trials include Panitumumab (ABX-EGF), a human antibody therapeutic product candidate directed against the epidermal growth factor receptor and a candidate for the treatment of various solid tumors; and ABX-10241 (ABX-PTH), a fully human antibody therapeutic product candidate directed against parathyroid hormone for the treatment of a secondary hyperparathyroidism. The company was founded in 1996 and is headquartered in Fremont, California.